Read about Supernus Pharmaceuticals Inc (SUPN:XNAS) stock and today's latest news and financial updates.

Of the 327 patient records screened, 224 met the study's inclusion criteria. Sixty-eight patients (30%) received prophylactic ondansetron 8 mg as antiemetic therapy in conjunction with ...

Advertising giant Havas is staying ahead of the curve. The company has launched a new campaign hailing neurodiversity as the future of the creative industry, and it recently took to the world’s ...

Supernus Pharmaceuticals’ first quarter results were met with a negative market reaction, despite revenue and non-GAAP profit exceeding Wall Street’s expectations. Management attributed the quarter’s ...

Supernus Pharmaceuticals’ first quarter results were met with a negative market reaction, despite revenue and non-GAAP profit exceeding Wall Street’s expectations. Management attributed the ...

Supernus Pharmaceuticals’ first quarter results were met with a negative market reaction, despite revenue and non-GAAP profit exceeding Wall Street’s expectations. Management attributed the quarter’s ...

Under the terms of the agreement, Sage will be acquired by Supernus Pharmaceuticals, Inc. (Nasdaq - SUPN). Supernus will commence a tender offer to acquire all of the outstanding shares of Sage ...

Palonosetron is clinically superior in controlling chemotherapy-induced nausea and vomiting, but how does its drug price ratio compare to other therapies?

JPMorgan cut its price target on Sage Therapeutics to $8.5 from $11 based on the recently announced buyout by Supernus Pharmaceuticals, representing an 8.5% downside from the last close. The ...

A Different Perspective We're pleased to report that Supernus Pharmaceuticals shareholders have received a total shareholder return of 20% over one year. Since the one-year TSR is better than the five ...